Header Logo

Connection

THOMAS WESTBROOK to Mice

Back to Details
This is a "connection" page, showing publications THOMAS WESTBROOK has written about Mice.
THOMAS WESTBROOK
Connection Strength
0.447
Mice
  1. MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast Cancer. Cancer Discov. 2024 Sep 04; 14(9):1699-1716.
    View in: PubMed
    Score: 0.067
  2. The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32.
    View in: PubMed
    Score: 0.034
  3. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.
    View in: PubMed
    Score: 0.028
  4. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature. 2008 Mar 20; 452(7185):370-4.
    View in: PubMed
    Score: 0.021
  5. An in vivo screen identifies NAT10 as a master regulator of brain metastasis. Sci Adv. 2025 Mar 28; 11(13):eads6021.
    View in: PubMed
    Score: 0.017
  6. IRE1a silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024 Dec 12; 187(25):7248-7266.e34.
    View in: PubMed
    Score: 0.017
  7. DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells. Nat Cell Biol. 2023 04; 25(4):528-539.
    View in: PubMed
    Score: 0.015
  8. E7 abolishes raf-induced arrest via mislocalization of p21(Cip1). Mol Cell Biol. 2002 Oct; 22(20):7041-52.
    View in: PubMed
    Score: 0.015
  9. Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Res Commun. 2021 12; 1(3):178-193.
    View in: PubMed
    Score: 0.014
  10. Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol Cell. 2021 08 05; 81(15):3048-3064.e9.
    View in: PubMed
    Score: 0.013
  11. ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. Cancer Discov. 2021 09; 11(9):2200-2215.
    View in: PubMed
    Score: 0.013
  12. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021 01 21; 184(2):384-403.e21.
    View in: PubMed
    Score: 0.013
  13. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol. 2021 02 18; 28(2):134-147.e14.
    View in: PubMed
    Score: 0.013
  14. Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6. Oncogene. 2020 04; 39(18):3726-3737.
    View in: PubMed
    Score: 0.012
  15. Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat Cell Biol. 2020 02; 22(2):225-234.
    View in: PubMed
    Score: 0.012
  16. Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. Cell Rep. 2019 10 08; 29(2):249-257.e8.
    View in: PubMed
    Score: 0.012
  17. A Druggable Genome Screen Identifies Modifiers of a-Synuclein Levels via a Tiered Cross-Species Validation Approach. J Neurosci. 2018 10 24; 38(43):9286-9301.
    View in: PubMed
    Score: 0.011
  18. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 2018 04; 556(7700):249-254.
    View in: PubMed
    Score: 0.011
  19. Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns. Cell. 2018 04 05; 173(2):499-514.e23.
    View in: PubMed
    Score: 0.011
  20. TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. Elife. 2016 10 25; 5.
    View in: PubMed
    Score: 0.010
  21. Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model. Neuron. 2016 Oct 19; 92(2):407-418.
    View in: PubMed
    Score: 0.010
  22. Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol. 2016 06; 18(6):632-44.
    View in: PubMed
    Score: 0.009
  23. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015 Sep 17; 525(7569):384-8.
    View in: PubMed
    Score: 0.009
  24. Tcf3 promotes cell migration and wound repair through regulation of lipocalin 2. Nat Commun. 2014 Jun 09; 5:4088.
    View in: PubMed
    Score: 0.008
  25. Plk2 regulates mitotic spindle orientation and mammary gland development. Development. 2014 Apr; 141(7):1562-71.
    View in: PubMed
    Score: 0.008
  26. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature. 2013 Jun 20; 498(7454):325-331.
    View in: PubMed
    Score: 0.008
  27. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
    View in: PubMed
    Score: 0.007
  28. An animal model of MYC-driven medulloblastoma. Cancer Cell. 2012 Feb 14; 21(2):155-67.
    View in: PubMed
    Score: 0.007
  29. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70.
    View in: PubMed
    Score: 0.007
  30. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009 May 29; 137(5):835-48.
    View in: PubMed
    Score: 0.006
  31. A resource for large-scale RNA-interference-based screens in mammals. Nature. 2004 Mar 25; 428(6981):427-31.
    View in: PubMed
    Score: 0.004
  32. Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest. J Virol. 2002 Jan; 76(2):619-32.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.